Skip to main content

Beta cell preservation via antigen-specific immunotherapy in Type 1 Diabetes: Enhanced Epidermal Antigen Delivery Systems

Objective

Current approaches to improving glycaemic control in type 1 diabetes are centered on increasingly complex insulin delivery systems. However, less than 30% of patients can achieve target levels of glucose control with this approach even in a clinical trial setting and many patients are either unable or unwilling to make the personal commitment required. By contrast, preservation of even small amounts of endogenous insulin production, has been shown to improve glycaemic control, reduce hypoglycaemia, improve quality of life and reduce long-term complications. Importantly, glycemic control in the presence of endogenous beta cell function is not demanding and hence would be effective across the full spectrum of individuals. Antigen specific immunotherapy (ASI) is the preferred approach to beta cell preservation since this avoids the risks of immunosuppression. Attempts at ASI to date although successful in preclinical models have had limited efficacy in humans. There is therefore an urgent need for the development of novel approaches to deliver effective ASI.
Our Enhanced Epidermal – Antigen Specific Immunotherapy (EE-ASI) system represents an innovative approach to ASI created by combining technologies brought by our academic and 2 SME partners. A beta cell target T cell epitope (proinsulin C19-A3) will be combined with the tolerogenic cytokine IL-10 and targeted to antigen presenting cells via gold nanoparticles and delivery into the very superficial layers of the skin using microneedles. Validation of manufacture, in vitro and in vivo preclinical efficacy will be demonstrated followed by a phase 1 clinical trial to confirm safety in humans.
We anticipate that the EE-ASI system will be less costly, more effective and more acceptable to patients in improving glycaemic control than exogenous insulin replacement. Intellectual property, regulatory and ethical issues will be carefully addressed in order to maximise exploitation of this integrated system for the benefit of the SMEs.

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Coordinator

CARDIFF UNIVERSITY
Address
Newport Road 30-36
CF24 ODE Cardiff
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 929 975
Administrative Contact
Nick Bodycombe (Mr.)

Participants (7)

INSERM TRANSFERT SA
France
EU contribution
€ 386 871
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jerome Weinbach (Dr.)
MIDATECH LTD
United Kingdom
EU contribution
€ 1 059 000
Address
Oddfellows House 19 Newport Road
CF24 0AA Cardiff
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stéphane Jallat (Dr.)
NANOPASS TECHNOLOGIES LTD
Israel
EU contribution
€ 807 200
Address
Golda Meir Street 3
74036 Nes Tziona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Yotam Levin (Dr.)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 315 000
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Bart O Roep (Prof.)
KING'S COLLEGE LONDON
United Kingdom
EU contribution
€ 583 825
Address
Strand
WC2R 2LS London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Paul Labbett (Mr.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 515 000
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Dominique Nobile (Mr.)
Universidad Politécnica de Cataluña
Sweden
EU contribution
€ 387 000
Address
Campus Valla
581 83 Linkoping
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gunilla Avefeldt (Ms.)